Clinuvel Pharmaceuticals Limited (CUV.AX)

14.38 -0.91 (-5.95%) At close: 04:10PM AEST

Clinuvel Pharmaceuticals Limited

535 Bourke Street
Level 22
Melbourne, VIC 3000
Australia
61 3 9660 4900
https://www.clinuvel.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Philippe Jacques Wolgen M.B.A., M.D.	CEO, MD & Director	2.78M	N/A	1963
Mr. Darren Michael Keamy B.Com., CPA	CFO & Company Secretary	415.08k	N/A	1973
Dr. Dennis J. Wright	Chief Scientific Officer	340.5k	N/A	N/A
Mr. Lachlan Hay	Director of Global Operations	N/A	N/A	N/A
Mr. Malcolm Bull	Head of Australian Operations & Investor Relations	N/A	N/A	N/A
Dr. Rose Quadbeck-Diel	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. Azza Hamila	Head of Quality & Drug Safety	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Corporate governance

Clinuvel Pharmaceuticals Limited’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.